Vipshop Not Done De...
Health Care: Drugs
Optimer Pharmaceuticals Inc. (OPTR: NASDAQ)
$14.43 -0.27 | -1.84%
05/21/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -37.27M | 5.93M | -48.54M | -42.23M |
| Operating Gains/Losses | -53.47M | 21.68K | -25.51K | 20.27K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 49.12M | -58.85M | 30.61K | 127.14K |
| (Increase) Decrease in Inventories | -11.11M | -3.95M | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -2.27M | 26.62M | -2.96M | -162.58K |
| (Decrease) Increase In Other Current Liabilities | 890.84K | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 416.66K | -881.54K | -9.43K | -512.00 |
| Other Non-Cash Items | 16.46M | 15.08M | 9.64M | 2.81M |
| Net Cash From Continuing Operations | -38.88M | -18.77M | -41.68M | -39.02M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -38.88M | -18.77M | -41.68M | -39.02M |
| Sale of Property, Plant & Equipment | 83.50K | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 68.54M | 42.16M | 46.84M | 30.15M |
| Purchases of Property, Plant & Equipment | -2.90M | -2.44M | -305.99K | -215.76K |
| Acquisitions | 57.37M | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -3.80M | -91.28M | -55.28M | -28.57M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 119.29M | -51.55M | -8.75M | 1.37M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 6.88M | 82.85M | 52.80M | 37.93M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 6.88M | 82.85M | 52.80M | 37.93M |
| Effect of Exchange Rate Changes | 372.22K | -597.58K | 433.47K | -3.42K |
| Net Change in Cash & Cash Equivalents | 87.66M | 11.93M | 2.81M | 275.45K |
Portfolios with OPTR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
Latest OPTR Headlines from TheStreet
- 3 Biotech Stocks Spiking With Big Volume 05.13.13 | 02:05 pm
- 3 Biotech Stocks Rising on Big Volume 02.27.13 | 02:02 pm
- 10 Biotech Stocks With A History Of Beating Earning Expectations 01.10.13 | 07:01 pm
- 5 Biotech Stocks Rising on Unusual Volume 11.20.12 | 02:11 pm
- 5 Stocks Moving Higher on Big Volume 09.04.12 | 02:09 pm
- Optimer Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript 07.31.12 | 10:07 pm
- Optimer Pharmaceuticals Inc. Stock Downgraded (OPTR) 05.17.12 | 05:05 am
- 5 Earnings Stocks Poised to Pop 05.09.12 | 10:05 am
- 7 Stocks Spiking on Unusual Volume 04.25.12 | 01:04 pm
- Optimer Pharmaceuticals Inc. Stock Upgraded (OPTR) 03.09.12 | 04:03 am
Press Releases for OPTR
- Optimer Pharmaceuticals Appoints Eric Sirota As Chief Operating Officer - PR Newswire 05.13.13 | 04:05 pm
- Optimer Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results - PR Newswire 05.02.13 | 08:05 am
- DIFICID® (fidaxomicin) Tablets Approved In Australia - PR Newswire 04.26.13 | 08:04 am
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 03.15.13 | 08:03 am
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 02.27.13 | 08:02 am
- Optimer Pharmaceuticals' Board Of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer - PR Newswire 02.27.13 | 08:02 am
- New Analysis Shows Age Has A Significant Effect On Outcomes In Patients Being Treated For Clostridium Difficile Infection (CDI) - PR Newswire 02.14.13 | 08:02 am
- Optimer Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year 2012 Financial Results - PR Newswire 02.07.13 | 08:02 am
- Optimer Pharmaceuticals To Present At Leerink Swann Global Healthcare Conference - PR Newswire 02.07.13 | 08:02 am
- Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire 02.01.13 | 08:02 am
Partner Headlines for OPTR
- Narrower Loss at Optimer - Analyst Blog - Zacks 11.02.12 | 05:11 pm
- Pipeline Progress at Cubist Pharma - Analyst Blog - Zacks 11.01.12 | 06:11 pm
- Earnings Preview: Cubist Pharma - Analyst Blog - Zacks 10.17.12 | 09:10 am
- Optimer Pharma to Sell Optimer Bio Stake - Analyst Blog - Zacks 10.09.12 | 07:10 pm
- UPDATE: Oppenheimer Downgrades Optimer Pharmaceuticals to Perform on Near-Term Outlook - Benzinga 10.09.12 | 01:10 pm
- UPDATE: Morgan Stanley Initiates Optimer Pharmaceuticals at Underweight on Risk/Reward - Benzinga 10.04.12 | 01:10 pm
- How one bull is playing Optimer Pharma - NASDAQ 09.11.12 | 09:09 am
- Optimer's Dificid OK'd in Canada - Analyst Blog - Zacks 07.09.12 | 07:07 pm
- Optimer Earns Milestone Payment - Analyst Blog - Zacks 06.08.12 | 04:06 pm
- UPDATE: Ladenburg Thalmann Maintains Buy Rating, Raises PT for Optimer Pharmaceuticals - Benzinga 05.11.12 | 09:05 am
